Anja Eckstein
YOU?
Author Swipe
View article: Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Open
Context Interleukin (IL)-17, a key proinflammatory cytokine, drives inflammation and fibrosis in Graves orbitopathy (GO), and elevated IL-17 and Th17 cells correlate with disease activity and severity. Objective The ORBIT study aimed to ev…
View article: Assessment of disease activity in Graves’ orbitopathy
Assessment of disease activity in Graves’ orbitopathy Open
Purpose Graves’ orbitopathy (GO) is the most common extra-thyroidal manifestation of Graves’ disease (GD). Clinical disease activity and severity stage at the time of diagnosis are commonly used to determine the optimal treatment. There ar…
View article: Real world effectiveness of Mycophenolate-sodium therapy in patients at risk with Graves’ orbitopathy
Real world effectiveness of Mycophenolate-sodium therapy in patients at risk with Graves’ orbitopathy Open
Purpose Patients with active, moderate-to-severe Graves’ orbitopathy require immunosuppressive treatments to reduce inflammation and morbidity. Since 2021 EUGOGO lists Mycophenolate-sodium (MPS) as first-line-treatment, which lead to a cha…
View article: Treatment Outcomes of Patients with Orbital Inflammatory Diseases: Should Steroids Still Be the First Choice?
Treatment Outcomes of Patients with Orbital Inflammatory Diseases: Should Steroids Still Be the First Choice? Open
Objective: To clarify the therapy response in orbital inflammatory diseases (OID), we analyzed the treatment effects of steroid therapy, the use of disease-modifying antirheumatic drugs (DMARDS), and biologicals in our tertiary referral ce…
View article: MR Imaging Characteristics of Solitary Fibrous Tumors of the Orbit
MR Imaging Characteristics of Solitary Fibrous Tumors of the Orbit Open
Purpose Solitary fibrous tumor (SFT) of the orbit is a rare tumor that was first described in 1994. We aimed to investigate its imaging characteristics that may facilitate the differential diagnosis between SFT and other types of orbital t…
View article: How Age Affects Graves’ Orbitopathy—A Tertiary Center Study
How Age Affects Graves’ Orbitopathy—A Tertiary Center Study Open
Purpose: Graves’ orbitopathy (GO) is an autoimmune disorder leading to inflammation, adipogenesis, and fibrosis. The severity of GO can vary widely among individuals, making it challenging to predict the natural course of the disease accur…
View article: Evaluation of a Retinal Projection Laser Eyeware in Patients with Visual Impairment Caused by Corneal Diseases in a Randomized Trial
Evaluation of a Retinal Projection Laser Eyeware in Patients with Visual Impairment Caused by Corneal Diseases in a Randomized Trial Open
The author(s) have no proprietary or commercial interest in any materials discussed in this article.
View article: Long-Term Follow-Up of Patients with Conjunctival Lymphoma after Individualized Lens-Sparing Electron Radiotherapy: Results from a Longitudinal Study
Long-Term Follow-Up of Patients with Conjunctival Lymphoma after Individualized Lens-Sparing Electron Radiotherapy: Results from a Longitudinal Study Open
Irradiation with electrons is the primary treatment regime for localized conjunctival low-grade lymphomas. However, radiation-induced cataracts are a major cause of treatment-related morbidity. This study investigates whether lens-sparing …
View article: OR26-03 Treatment With Linsitinib, An IGF-1 Receptor Inhibitor, Prevents Disease Development And Progression In An Experimental Model Of Thyroid Eye Disease
OR26-03 Treatment With Linsitinib, An IGF-1 Receptor Inhibitor, Prevents Disease Development And Progression In An Experimental Model Of Thyroid Eye Disease Open
Disclosure: A. Gulbins: Grant Recipient; Self; Sling therapeutics, Inc. M. Horstmann: Grant Recipient; Self; Sling therapeutics, Inc. A. Daser: None. U. Flögel: None. M. Oeverhaus: Grant Recipient; Self; Sling therapeutics, Inc. B.E. Nikol…
View article: Potential involvement of the bone marrow in experimental Graves’ disease and thyroid eye disease
Potential involvement of the bone marrow in experimental Graves’ disease and thyroid eye disease Open
Introduction Graves’ disease is an autoimmune disorder caused by auto-antibodies against the thyroid stimulating hormone receptor (TSHR). Overstimulation of the TSHR induces hyperthyroidism and thyroid eye disease (TED) as the most common …
View article: Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease
Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease Open
Context Inhibition of the neonatal fragment crystallizable receptor (FcRn) reduces pathogenic thyrotropin receptor antibodies (TSH-R-Ab) that drive pathology in thyroid eye disease (TED). Objective We report the first clinical studies of a…
View article: Evaluation of [<sup>68</sup>Ga]-DOTATOC PET/MRI in Patients with Meningioma of the Subcranial and Intraorbital Space
Evaluation of [<sup>68</sup>Ga]-DOTATOC PET/MRI in Patients with Meningioma of the Subcranial and Intraorbital Space Open
Meningiomas are known to express somatostatin receptor (SSTR) type 2 to a high degree. Therefore, radiolabeled somatostatin analogs, such as DOTATOC, have been introduced for PET imaging of meningiomas. However, the benefit of hybrid SSTR …
View article: Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease
Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease Open
Introduction Graves’ disease (GD) is an autoimmune disorder caused by autoantibodies against the thyroid stimulating hormone receptor (TSHR) leading to overstimulation of the thyroid gland. Thyroid eye disease (TED) is the most common extr…
View article: Treatment with linsitinib, an IGF-1 receptor inhibitor, attenuates disease development and progression in an experimental model of Graves’ Orbitopathy
Treatment with linsitinib, an IGF-1 receptor inhibitor, attenuates disease development and progression in an experimental model of Graves’ Orbitopathy Open
Study objective The activity of linsitinib, a small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R), was assessed in a mouse model of Graves’ orbitopathy (GO). GO is the most common extra-thyroidal manifestation of…
View article: Sphingolipids in thyroid eye disease
Sphingolipids in thyroid eye disease Open
Graves’ disease (GD) is caused by an autoimmune formation of autoantibodies and autoreactive T-cells against the thyroid stimulating hormone receptor (TSHR). The autoimmune reaction does not only lead to overstimulation of the thyroid glan…
View article: Influence of biological sex, age and smoking on Graves’ orbitopathy – a ten-year tertiary referral center analysis
Influence of biological sex, age and smoking on Graves’ orbitopathy – a ten-year tertiary referral center analysis Open
Purpose Severity of Graves’ orbitopathy (GO) shows wide individual differences. For optimal treatment, it is important to be able to predict the natural course of the disease as accurate as possible to counteract with anti-inflammatory and…
View article: Low-dose AtropIne for Myopia Control in Children (AIM): protocol for a randomised, controlled, double-blind, multicentre, clinical trial with two parallel arms
Low-dose AtropIne for Myopia Control in Children (AIM): protocol for a randomised, controlled, double-blind, multicentre, clinical trial with two parallel arms Open
Introduction Myopia is a major cause of degenerative eye disease and increases the risk of secondary visual impairment. Mitigating its progression therefore has great potential of clinically relevant benefit as shown by using highly dilute…
View article: MRI-based long-term follow-up of indolent orbital lymphomas after curative radiotherapy: imaging remission criteria and volumetric regression kinetics
MRI-based long-term follow-up of indolent orbital lymphomas after curative radiotherapy: imaging remission criteria and volumetric regression kinetics Open
We systematically analyzed the kinetics of tumor regression, the impact of residual lesions on disease control and the applicability of the Lugano classification in follow-up MRI of orbital non-Hodgkin lymphomas that were irradiated with p…
View article: Management of carotid cavernous fistulas: A single center experience
Management of carotid cavernous fistulas: A single center experience Open
Purpose Multimodal endovascular therapy (EVT) of carotid cavernous fistula (CCF) with different approaches and a variety of available embolization material enable high occlusion rates with good clinical and functional outcome but until now…
View article: Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study
Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study Open
Context Gut bacteria can influence host immune responses but little is known about their role in tolerance-loss mechanisms in Graves disease (GD; hyperthyroidism caused by autoantibodies, TRAb, to the thyrotropin receptor, TSHR) and its pr…
View article: Presentation of Graves’ orbitopathy within European Group On Graves’ Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III)
Presentation of Graves’ orbitopathy within European Group On Graves’ Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III) Open
Background Graves’ orbitopathy (GO) is subject to epidemiological and care-related changes. Aim of the survey was to identify trends in presentation of GO to the European Group On Graves’ Orbitopathy (EUGOGO) tertiary referral centres and …
View article: Macrophage-Orbital Fibroblast Interaction and Hypoxia Promote Inflammation and Adipogenesis in Graves’ Orbitopathy
Macrophage-Orbital Fibroblast Interaction and Hypoxia Promote Inflammation and Adipogenesis in Graves’ Orbitopathy Open
The inflammatory eye disease Graves’ orbitopathy (GO) is the main complication of autoimmune Graves’ disease. In previous studies we have shown that hypoxia plays an important role for progression of GO. Hypoxia can maintain inflammation b…
View article: Radioiodine Ablation of Thyroid Remnants in Patients with Graves’ Orbitopathy
Radioiodine Ablation of Thyroid Remnants in Patients with Graves’ Orbitopathy Open
Our purpose was to assess response after ablation of thyroid remnants (ATR) with radioactive iodine therapy in patients with unstable Graves' orbitopathy (GO) after subtotal thyroidectomy. Methods: Thirty patients with mild (n = 4, 13%), m…
View article: Novel Insights into Pathophysiology of Orbital Inflammatory Diseases and Progression to Orbital Lymphoma by Pathway Enrichment Analysis
Novel Insights into Pathophysiology of Orbital Inflammatory Diseases and Progression to Orbital Lymphoma by Pathway Enrichment Analysis Open
Non-specific orbital inflammation (NSOI) and IgG4-related orbital disease (IgG4-ROD) are currently treated with non-specific immunosuppressive agents based on non-randomized, uncontrolled studies. Therefore, relapses and prolongated course…
View article: Incidence of A pattern strabismus after inferior rectus recession in patients with Graves' orbitopathy: A retrospective multicentre study
Incidence of A pattern strabismus after inferior rectus recession in patients with Graves' orbitopathy: A retrospective multicentre study Open
Introduction and purpose Patients with Graves' orbitopathy (GO) may develop restricted elevation; this can lead to hypotropia, sometimes in combination with an abnormal head posture. Recession of one or both inferior rectus muscles is the …
View article: Evaluation of Orbital Lymphoproliferative and Inflammatory Disorders by Gene Expression Analysis
Evaluation of Orbital Lymphoproliferative and Inflammatory Disorders by Gene Expression Analysis Open
Non-specific orbital inflammation (NSOI) and IgG4-related orbital disease (IgG4-ROD) are often challenging to differentiate. Furthermore, it is still uncertain how chronic inflammation, such as IgG4-ROD, can lead to mucosa-associated lymph…
View article: Long‐term follow‐up and health‐related quality of life among cancer survivors with stage IEA orbital‐type lymphoma after external photon‐beam radiotherapy: Results from a longitudinal study
Long‐term follow‐up and health‐related quality of life among cancer survivors with stage IEA orbital‐type lymphoma after external photon‐beam radiotherapy: Results from a longitudinal study Open
We assessed the long‐term outcomes and treatment‐related adverse effects of patients with Stage I, “orbital‐type” lymphomas that were uniformly treated with photons. All consecutive patients diagnosed with low‐grade, Ann Arbor Stage IEA or…